Notice. The research described in this plan will be funded by the US Environmental Protection Agency. This document has been subjected to the Agency's peer and administrative review and approved for publication. Mention of trade names or commercial products does not constitute endorsement nor recommendation for use.

ii DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document may undergo revisions in the future. The most up-to-date version will be made available electronically via the IRIS Home Page at

Any use of trade, product, or firm names in this publication is for descriptive purposes and does not imply endorsement by the U.S. Government. Although this report is in the public domain, permission must be secured from the individual copyright owners to reproduce any copyrighted material contained within this report. This report has not been reviewed for stratigraphic nomenclature.

1999 This report is preliminary and has not been reviewed for conformity with U.S. Geological Survey editorial standards or with the North American Stratigraphic Code. Any use of trade, firm, or product names is for descriptive purposes only and does not imply endorsement by the U.S. Government.

policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document represents the final guidelines. A number of editorial corrections have been made during conversion and subsequent proofreading to ensure the accuracy of this publication.

2 DISCLAIMER Certain trade names and company products are mentioned in the text or identified in certain illustrations. In no case does such an identification imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the products are necessarily the best available for the purpose.

policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document represents the final guidelines. A number of editorial corrections have been made during conversion and subsequent proofreading to ensure the accuracy of this publication.

IN T RODUC T ION Desmopressin (1-desamino-8-D-arginine vasopressin), Figure 1, (trade names: DDAVP, Stimate, Minirin) is a peptide containing nine amino acids, a form of the normal human hormone arginine vasopressin that reduces urine production. It may be taken nasally, intravenously, or as a tablet. Desmopressin is most commonly prescribed for the treatment of diabetes insipidus or nocturnal ...

NOTICES Disclaimers The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents. Citation of manufacturer's or trade names does not constitute an official endorsement or approval of the use thereof. Destroy this report when it is no longer needed. Do not return it to the originator.